Apolipoprotein A-1 (apoA-1) is the principal protein fraction of high-density lipoprotein (HDL), conferring to the latter many of its pleiotropic atheroprotective functions. After its effect on cholesterol efflux, the second most studied feature of apoA-1 is its anti-inflammatory property. In addition, it interferes with lipid peroxidation and innate immune receptors. These anti-inflammatory effects are due to various properties, in particular the ability to inhibit the transendothelial migration of immune cells by reducing integrin expression, to inhibit monocyte activation and cytokine production induced by T-cell contact, to inhibit lipid peroxidation and to interfere with innate immune receptors. Recent studies have demonstrated that during chronic systemic inflammation HDL could lose some of its atheroprotective functions and become dysfunctional or even proinflammatory. Recent evidence suggests that specific posttranslational modifications of apoA-1 transform this genuine anti-inflammatory molecule into a proinflammatory one. The structural changes include chlorination, nitration and carbamylation of amino acids by myeloperoxidase, oxidation by reactive carbonyls, as well as glycation. Humoral autoimmunity to apoA-1 and HDL has been reported in populations at high cardiovascular risk and constitutes another emerging mechanism contributing to the loss of functions of apoA-1 and HDL. The fact that in recent trials cholesteryl ester transfer protein inhibitors (torcerapib and dalcetrapib) have unfortunately failed to prevent cardiovascular disease despite increasing cholesterol efflux in vitro and HDL levels in vivo, further highlights the clinical importance of understanding the mechanisms driving apoA-1 and HDL towards pro-or anti-inflammatory molecules. These findings should not affect current dyslipidaemia management guidelines.
Introduction
Apolipoprotein A-1 (apoA-1) constitutes the principal protein fraction of high-density lipoprotein (HDL) whose protective role in the cardiovascular system derives to a great extent from the inverse relationship between HDL-cholesterol and apoA-1 plasma concentrations, and a risk of myocardial infarction [1] . The atheroprotective role of HDL in the cardiovascular system has been attributed to its pleiotropic effects, including reverse cholesterol transport, vasodilatation, and antithrombotic, anticoagulant and antiinflammatory effects [2] . Mirroring those versatile properties, mass spectrometry analyses revealed that HDL encompasses very heterogeneous macromolecular complexes of lipids and proteins. Only one-third of the up to 80 different proteins identified in HDL is dedicated to lipid transport. The remaining proteins are either acute-phase proteins, proteases, antioxidant or antithrombotic enzymes, or proteins involved in complement regulation [3] . As well as being the principal protein fraction of HDL and a limiting factor for HDL formation, apoA-1 per se has many of the HDL-related atheroprotective properties [4] . Apart from its pivotal role in reverse cholesterol transport (RCT), where it induces cholesterol efflux via an adenosine triphosphate (ATP) binding cassette transporter and activates lecithin:cholesterol acyltransferase (LCAT) [5] , the second best-studied property of apoA-1 is its mitigating effect on inflammation through several pathways [2] [3] [4] . However, there is a growing body of evidence that both acute and chronic inflammatory conditions induce posttranslational modifications of apoA-1. These, in turn, not only dampen the functions regulating lipid homoeostasis and the anti-inflammatory properties of HDL/ApoA-1, but even turn it into a proinflammatory molecule [4] . Thus, HDL and apoA-1 appear to contribute to host defence against many biological and chemical hazards. However, analogous to failing or erroneous host defences through leukocytes and their humoral mediators, the protective activities of HDL can be compromised and made to fail, or even perverted to harm. The literature regarding apoA-1 is complex and often blurred by the fact that biological activities are frequently attributed to apoA-1 alone, to apoA-1 in association with different lipids or even to HDLs. Therefore, the aim of the present paper is to review specifically the pathways by which apoA-1 per se or as part of HDL acts as an anti-inflammatory molecule, and to analyse the translational and post-translational modifications to apoA-1 that could lead to a proinflammatory phenotype. Several natural apoA-1 variants have been described and some are characterised by alterations in lipid binding, LCAT activation and cholesterol efflux stimulation in vitro, as well as defective HDL formation in vivo. However, these are out of the scope of this review, and will not be discussed here.
Structure and biology of apolipoprotein A-1
Human apoA-1 is a 28-kD protein with 243 amino acid residues encoded by the apolipoprotein multigene superfamily located on chromosome 11q23 [6] . The protein is synthesised as a preprosequence of apoA-1 (24 amino acid residues longer), primarily by hepatocytes in the liver and also by enterocytes. The largest part of its secondary structure consists of class A amphipathic α-helices separated by proline hinges. In these helices, apolar residues occupy one face whereas polar residues occupy the other face, and positively charged lysine and arginine residues separate the two faces of the helix. This amphipathic structure allows the interaction of apoA-1 with lipids through its hydrophobic faces and with the aqueous phase through its hydrophilic faces. The proline hinges confer a high steric flexibility on the apoA-1 molecule, allowing important conformational changes needed to occupy both discoidal and spherical HDL particles of different sizes [7] . Upon maturation, HDL undergoes conformational changes accompanied by important functional changes, enabling interaction with a wide range of different proteins including ATP binding cassette transporters A1 (ABCA1) and G1 (ABCG1), as well as LCAT and scavenger receptor B1 (SR-B1), which are expressed mostly by hepatocytes and macrophages [8] [9] [10] . Lipid-free apoA-1 represents up to 10% of circulating apoA-1 [9] , which is present in plasma in normal conditions at a concentration of 90-250 mg/dl, slightly higher in women than in men. In pathological conditions apoA-1 behaves as a negative ("reverse") acute-phase protein, that is, a protein whose level is lowered by more than 25% during the acute-phase response and thought to be displaced by serum amyloid A (SAA) which is a "positive" acutephase protein [11] . However, it was demonstrated subsequently that during the acute-phase response, proinflammatory cytokines increase the expression of SAA, while simultaneously decreasing the expression of apoA-1 and paraoxonase 1 (PON-1), which suggests that the reduction in apoA-1 during the acute-phase response is not only due to physical displacement of apoA-1, but to inverse transcriptional regulation in the liver [12] . Site-directed mutagenesis studies resulted in the identification of structural domains which specifically modulate the functionalities of apoA-1. So far, most reports have dealt with the effects of lipid-free apoA-1 and apoA-1-related mimetic peptides on cholesterol efflux models mediated by ABCA1 as well as LCAT activation [9] , for which the Cterminal (amino acid residues (aa): 187-243) and central domains (aa: 143-165), respectively, are important [13] . The N-terminal part of lipid-free apoA-1 (aa: 1-98) has been shown to be essential for stabilising its lipid-free conformation, as well as for lipid interaction [14] [15] [16] . Furthermore, stabilising the α-helix of apoA-1 mimetic peptides translated into higher cholesterol efflux efficacy, further confirming that the conformational state of apoA-1 is crucial for its function in regard to cholesterol efflux [17] .
ApoA-1 as an anti-inflammatory molecule
HDLs have been considered to be anti-inflammatory molecules for 20 years [18] . However, whether these effects are mainly due to the lipid (for example, sphingosine-1-phosphate) or the protein constituents of HDL (apoA-1, but also quantitatively minor proteins such as paraoxonase (PON) or clusterin) is still a matter of debate. In the following paragraphs, we will review only the specific anti-inflammatory properties of HDL/apoA-1.
Inhibition of transendothelial migration of immunocompetent cells
In the mid-nineties, apoA-1 was observed to display antiinflammatory properties by inhibiting the cytokine-induced expression of cell adhesion molecules such as vascular cell adhesion molecule-1 (VCAM-1), intercellular adhesion molecule-1 (ICAM-1) and E-selectin, which are key players in diapedesis of immunocompetent cells from the circulation into the artery wall [19] . Since the latter phenomenon is considered to be one of the earliest events in atherogenesis, those seminal findings raised the possibility that apoA-1 could represent an innovative therapeutic alternative for preventing atherosclerosis at an early stage. They also provided initial evidence for an atheroprotective role of apoA-1 independent of cellular cholesterol homeostasis regulation. Later on, the same group demonstrated that apoA-1 or phospholipids per se were not sufficient to exert the anti-inflammatory properties of lipidpoor apoA-1, so that for optimal function both must coexist on one particle. In line with this, the shape of apoA-1containing HDLs also influences the anti-inflammatory response, spherical apoA-1-containing HDLs being more anti-inflammatory than discoidal ones [19] . Those results were the first to indicate a significant role of the conformational state of apoA-1 and HDLs in ensuring the optimal mediation of their anti-inflammatory effects. Afterwards, it was shown that HDL/apoA-1 modulates the cytokine-induced integrin expression by activated endothelial cells, as extensively reviewed elsewhere [20] . ApoA-1 has been shown to inhibit both shear stress and phorbol-12 myristate 13-acetate (PMA) induced monocyte expression of CD11b, one of the integrins, complementary to VCAM-1 and ICAM-1, involved in the early stages of transendothelial migration. In this study, the dose-dependent inhibition of CD11b expression was accompanied by decreased transendothelial migration of monocytes toward chemotactic agents such as monocyte chemoattractant protein-1 (MCP-1). This activity was strongly dependent on ABCA1, but independent of SR-B1 signalling [21] . Those results confirmed and extended a previous observation that HDL inhibits LDL-induced MCP-1 production in monocytes as well as their subsequent transendothelial diapedesis [22] . Further insight into the molecular mechanisms underlying this phenomenon was gained from the observation that apoA-1 interaction with ABCA1 promoted signal transducer and activator of transcription (STAT-3) activation through janus kinase (JAK) 2, which ultimately abolished the lipopolysaccharide (LPS) induced proinflammatory response (such as interleukin (IL) 1β, IL-6, and tumour necrosis factor alpha (TNF-α) production by monocytes), without affecting cholesterol efflux [23] . Altogether, these results suggested that ABCA1 is not only involved in cholesterol metabolism, but also modulates the anti-inflammatory response of cells to apoA-1. The charge and size of the hydrophobic face of synthetic apoA-1 peptides are major factors affecting their anti-inflammatory properties. More specifically, inhibition of VCAM-1 expression was maximised by increasing the hydrophobic face size and the number of positively charged residues. Inhibition of CD11b expression in monocytes increased with asymmetry and hydrophobicity, but diminished with increasing numbers of positively charged residues, further emphasising the importance of apoA-1 conformation to the deployment of its anti-inflammatory properties [19, 24] . In conclusion, in specific conformations, apoA-1 can inhibit transendothelial migration of immunocompetent cells, both by blocking the production of chemotactic cytokines by monocytes and by impeding the expression by endothelial and monocytic cells of integrins required for efficient diapedesis in response to chemotactic agents.
Inhibition of T-cell contact-mediated monocyte activation
Once transendothelial migration of inflammatory cells has occurred, the interaction between monocyte-macrophages and T cells represents another important step in modulating the microenvironment of the chronic inflammatory response. Indeed, direct contact between activated T cells and monocytes/macrophages is a major driver for the production of several inflammatory cytokines, such as IL-1β, IL-6, IL-8, MCP-1 and TNF-α, which are well known for being involved in atherogenesis and tissue destruction [25, 26] . ApoA-1 has been shown to inhibit contact-mediated monocyte stimulation and the subsequent production of IL-1β and TNF-α. Although the exact mechanisms of action are not fully elucidated yet, the authors suggested that apoA-1 blocks T-cell/monocyte interactions at the T cell level [25] . This conclusion is in accordance with previous work suggesting the presence of a specific, but as yet unidentified, HDL binding site on human lymphocytes [27] . Additional studies in this model of cell-cell interaction demonstrated that HDL/apoA-1 inhibits T-cell contactactivated specific proinflammatory gene expression in monocytes [28] . In contrast, HDL/apoA-1 does not affect or inhibit -or only to a small extent -the expression of molecules displaying anti-inflammatory and regulatory functions such as IL-1 receptor antagonist (IL-1Ra). Microarray analysis shows that 437 out of 54,675 probe sets were enhanced in monocytes activated by contact with stimulated T cells of which 164 (i.e. 38%) were inhibited in the presence of HDL. These results were validated using real-time polymerase chain reaction (qPCR) [28] . These in-vitro observations were confirmed in vivo in various chronic and acute pathological conditions. For example, immunohistochemistry on synovial biopsies from rheumatoid arthritis patients revealed that apoA-1 was consistently present in inflamed synovial tissue that contained infiltrating T cells and macrophages, but was absent from noninflamed tissue samples obtained from treated patients and from normal subjects. ApoA-1 was not present in synovium from patients in apparent remission, which suggests that it has a specific role during phases of disease activity [29] . On the other hand, HDL/apoA-1 was markedly reduced in patients admitted to an intensive care unit for systemic inflammatory response syndrome. Patients with an exacerbated inflammatory state had significantly lower plasma levels of apoA-1 than those whose inflammation was not exacerbated, which suggests a protective role of apoA-1. Moreover, a correlation was established between the levels of apoA-1 in patients' sera and their in-vitro inhibitory effect on the release of IL-1β by T-cell-stimulated monocytes [30] . There is currently no information available as to the conformational requirements for apoA-1 to modulate the cell-cell contact inhibition. However, a specific blocking antibody to apoA-1 proved to interfere with the inhibitory action of HDL [30] .
Inhibition of lipid peroxidation
Another important step in inflammation and atherogenesis is the uptake of lipid peroxidation products by macrophages, with oxidised low-density lipoproteins (oxLDL) being key players in early and late stages of atherogenesis [31] [32] . The proatherogenic properties of oxLDLs consist mostly in fostering sterile inflammation through the activation of various innate immune receptors that trigger numerous signalling pathways, as extensively reviewed elsewhere [31] [32] . In 1979 it was demonstrated that HDLs are able to inhibit LDL oxidation [33] . Subsequent studies demonstrated that this feature was related to the presence of apoA-1 on HDL molecules, and that it could be fully reproduced by apoA-1 mimetic peptides [2] . This antioxidant property of apoA-1 is believed to be mainly, but not exclusively, due to PON-1, an enzyme associated with apoA-1 and known to prevent different kinds of lipid peroxidation [34] . Preserving the proline bridge on bihelical apoA-1 synthethic peptides was found to be detrimental to the antioxidant properties of the peptides, whereas modifications of the charge, the hydrophobicity, or the size of hydrophobic face had only a limited impact on the antioxidant capacity of those peptides [24] . Considering that antioxidant agents failed to prevent cardiovascular disease in randomised controlled trials, the clinical benefit of these antioxidant properties remains to be determined [35] .
Modulation of the innate immune response and Tolllike receptors
The innate immune response represents the first line of defence against infectious agents and modified autoantigens (modified/oxidised lipids and apoptotic cells), allowing their rapid clearance through lysosomal degradation, and at the same time drives the development of a more specific and efficient adaptive response. The innate immune system consists of both cellular and humoral components. Major cellular components are neutrophils, monocyte/macrophages, natural killer (NK) and lymphokine-activated killer (LAK) cells, and eosinophils. The humoral counterpart is mostly represented by the pentraxin family, the complement system and various cytokines. Three main classes of innate immune receptors have been described: Toll-like receptors (TLRs), scavenger receptors (SRs) and Nod-like receptors (NLRs). The former two are considered important mediators of the immune-mediated inflammation that characterises atherogenesis [36] [37] . Both HDL and apoA-1 have been shown to modulate either directly or indirectly the signalling of the innate immune system at different levels. As early as 1979, the effect of HDL on the innate immune system proved to reduce LPS toxicity in vivo [38] . In vitro, LPS stimulates substantially more IL-1 mRNA and cell-associated IL-1 protein when monocytes are stimulated with LPS alone than with LPS-HDL [39] . This activity was later attributed to the fact that HDL sequesters LPS and thereby prevents the transduction of the proinflammatory cascade through TLR4/CD14 complex interaction [40] . By using several apoA-1 mutants, apoA-1 was found to be the key component of HDL-related LPS neutralisation. Indeed, the N-terminal region (aa: 52-74) of apoA-1 was identified as being specific to this effect, without affecting cholesterol efflux from macrophages [41] . As well as preventing upstream TLR4 activation by impeding the interaction with its ligand, apoA-1 has also been shown to inhibit TLR4 signalling directly by impeding its transport into lipid rafts [42] . Although controversial, recent work identified apoA-1 not only as a circulating molecule, but also as a cellular molecule expressed in low amounts by macrophages. It has been localised in lipid rafts and in the vicinity of ABCA1 [43] . These authors reported that, by its spatially close association, apoA-1 stabilises the membrane expression of ABCA1. Moreover, suppressed endogenous apoA-1 was associated with increased expression of TLR4 at the mRNA level [43] . According to these findings, endogenous and circulating apoA-1 can modulate TLR4 signalling. To the best of our knowledge, such evidence is currently lacking for other TLRs. SRs were the first innate immune receptors known to have apoA-1 as one of their numerous ligands. Among them, SR-B1 is known to be an important effector of the various anti-inflammatory functions of HDL. Indeed, apoA-1/SR-B1 interaction is crucial for cholesterol efflux [22] , nitric oxide synthesis, glucocorticoid synthesis and TLR4 signalling [9-10, 44]. However, as discussed later in the proinflammatory section, apoA-1 interaction with SRs could have contradictory effects on inflammation control. Another important mechanism for the functionality of innate immune receptors is their targeting on functional lipid rafts, which allows their interaction with other coreceptors for the optimal activation downstream of specific signalling pathways. Accordingly, the integrity of lipid rafts has been shown to be crucial for appropriate proinflammatory TLR signalling [45] . In this respect, apoA-1 has been shown to induce cholesterol depletion from lipid rafts, thereby decreasing TLR4 functionality and inhibiting LPSinduced inflammatory responses [46] .
Modulation of the adaptive immune response
Because lipid rafts on antigen presenting cells (APCs) also concentrate major histocompatibility complex (MHC) class 2 molecules, which are known to play a crucial part in T-lymphocyte activation [47] , it can be hypothesised that apoA-1 may have a significant impact on the adaptive aspect of the immune response. Nevertheless, to the best of our knowledge, this appealing hypothesis has never been formally validated. Among other major players of the immune system, regulatory T cells (Tregs) are important components of the adaptive immune response, acting to maintain self-tolerance. Tregs suppress the activation of T cells by either a contact-dependent process involving APCs or secretion of anti-inflammatory cytokines such as IL-10 and transforming growth factor beta (TGF-β) [48] . The absence of, or defects in, Tregs can lead to inflammatory disease such as autoimmune disorders and atherosclerosis [48] . ApoA-1 -/-x LDL-receptor -/-double knock-out mice exhibit an autoimmune phenotype. In this model, administration of exogenous apoA-1 was found to prevent the differentiation of T cells into a proinflammatory Th17 phenotype, and to increase the Treg population. These anti-inflammatory effects at the cellular level were accompanied macroscopically by the restoration of a close-to-normal phenotype of skin architecture, morphology and composition [49] . The mechanisms underlying the beneficial effect of apoA-1 administration on Treg function are still unknown. As summarised in table 1, apoA-1 acts as a pleiotropic antiinflammatory agent by modulating the inflammatory response at the prereceptor, receptor and postreceptor levels, mainly on innate APCs. It also appears to act on the adaptive compartment by decreasing Th17 polarisation and promoting Treg expansion. As a consequence, apoA-1 can inhibit the production of proinflammatory cytokines, and the cell contact-mediated inflammatory response. It also prevents the generation of self-modified antigens by inhibiting the formation or persistence of lipid peroxidation products. Together, these effects have the potential ultimately to translate into reduced chemotaxis, diapedesis and inflammatory activity of immunocompetent cells at the site of inflammation.
ApoA-1 as a proinflammatory molecule
In both acute and chronic inflammation, HDL can become proinflammatory [4] , a phenomenon initially explained by the replacement of apoA-1 by serum amyloid A (SAA) protein, ceruloplasmin and haptoglobin [4] , with SAA representing up to 87% of HDL proteins [50] . These SAA-containing HDLs may be retained in the arterial intima through facilitated interaction with vascular proteoglycans, and are thus more extensively exposed to oxidative modifications. Recent studies reviewed in the next paragraphs demonstrate that other translational and post-translational modifications can turn apoA-1 into a proinflammatory molecule.
Amyloidosis as a human paradigm to study the pathogenicity of translational and post-translational apoA-1 modifications ApoA-1 is involved in two forms of amyloidosis, a disease affecting vital organs such as kidney, liver and heart; amyloidosis therefore constitutes a suitable human paradigm to investigate the pathophysiological consequences of apoA-1 modifications, both at the translational and post-translational levels. In both nonhereditary and hereditary amlyoidosis, modifications of apoA-1 (either through oxidation or proteolysis in the former, or through mutations
Figure 1
Mechanisms of apolipoprotein A-1 (apoA-1) carbamylation. MPO = myeloperoxidase in the latter, form of the disease) lead to the formation of amyloid fibrils/complexes found in various organs and in atherosclerotic plaques [51] . Although their involvement in inflammation and atherosclerosis is just beginning to be elucidated, it seems that newly formed amyloid complexes, fibrils or β-sheets are capable of inhibiting reverse cholesterol transport [52] and generate a strong proinflammatory response through the signalling receptor of advanced glycation end products (AGE) [53] . Nevertheless, those in vitro observations have not yet been validated by experimental evidence in vivo.
Post-translational apoA-1 modifications

ApoA-1 modifications driven by myeloperoxidase
Functionally relevant post-translational modifications of apoA-1 include chlorination, nitration and oxidation of tyrosine residues, which are catalysed by myeloperoxidase (MPO). ApoA-1 and HDL derived from patients with cardiovascular disease had a significantly higher content of MPO-dependent oxidative modifications, which are functionally associated with a reduced capacity of apoA-1 to bind to ABCA1 and to induce ABCA1-mediated choles-
Figure 2
The pro-and anti-inflammatory role of apolipoprotein A-1 (apoA-1) / high-density lipoprotein (LDL). CV = cardiovascular; IC = immune complexes; LDL = low-density lipoprotein; PTM = post-translational modifications; TLR = Toll-like receptor. Inhibition of endothelial integrin expression (VCAM1, ICAM1, E-selectin)
Not specified Yes, depends on the hydrophobic face size and the number of positively charged residues [19] [20] 24] Inhibition of monocytes integrin expression (CD11b) Not specified, but ABCA1 Dependent; C-terminal?
Yes, depends on the asymmetry and hydrophobic face size, and the negatively charged residues [21, 22] Lipid peroxidation Not specified Yes, depends on the presence of the proline bridge, determining the angle between helixes [33, 34, 24] T cell/Monocyte interaction Not specified Unknown [25, 26, 28] Increase Treg differentiation Not specified Unknown [49] Aa = amino acid residues; ABC = ATP binding cassette transporter; ATP = adenosine triphosphate; ICAM = intercellular adhesion molecule; LPS = lipopolysaccharide; SR = scavenger receptor; TLR = Toll-like receptor; Treg = regulatory T cell; VCAM = vascular cell adhesion molecule.
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Swiss Med Wkly. 2013;143:w13781 terol efflux [54] . Physiologically relevant concentrations of MPO may generate dysfunctional HDLs characterised by a reduced cholesterol efflux capacity [55] . These findings were the first to demonstrate a causal link between specific apoA-1 modifications inducing dysfunctional HDL and a proinflammatory status through a specific MPO-driven pathway.
Another post-translational HDL modification driven by MPO reported recently is carbamylation [56] , whose clinical relevance to cardiovascular disease, especially in renal failure patients, is well established [57] . Protein carbamylation is mediated by cyanate, which is in turn produced either by MPO or urea decomposition ( fig. 1 ). Carbamylated apoA-1 was found to be significantly increased in advanced atherosclerotic lesions when compared with vessels with early lesions, but no such differences in plasma HDL levels were noted between those groups. The authors also demonstrated that in-vitro carbamylation of apoA-1 inhibits SR-B1 but not ABCA1-mediated cholesterol efflux, leading to a marked cholesterol accumulation in THP-1 macrophages [57] . Those results constitute further evidence of apoA-1 modifications affecting HDL atheroprotective properties.
ApoA-1 modifications driven by reactive carbonyls
Reactive carbonyls can also generate specific apoA-1 products derived from oxidation/glycation. Reactive carbonyls are generated either by carbohydrate oxidation, which gives rise to proinflammatory AGE molecules [58] , or lipid peroxidation, which produces advanced lipoxidation end products (ALE) [58, 59] . Both ALE and AGE have been associated with diabetes and cardiovascular disease [58, 59] , and were shown to modify native apoA-1 in different but specific ways. Nobecourt and co-workers demonstrated that, after exposure to glycation and subsequent incorporation into discoidal reconstituted HDLs, apoA-1 lost its capacity to activate LCAT. This loss was associated with modifications of arginine, lysine and tryptophan residues [60] . Recently, the same group showed that apoA-1 glycation induced by methylglyoxal in vitro or in vivo resulted in apoA-1 failing to inhibit both the infiltration of neutrophils into the intima of rabbit carotid arteries and the expression of ICAM-1 and VCAM-1 in endothelial cells. This effect was accompanied by increased nuclear NF-κB translocation when compared with native apoA-1, and a reduced ability to inhibit the formation of reactive oxygen species (ROS) [61] . When exposed to methylglyoxal, reconstituted HDLs displayed the same loss of function of their anti-inflammatory properties when compared with lipid-free apoA-1, suggesting that those apoA-1 modifications driven by carbonyl-reactive species can generate dysfunctional HDL in terms of cholesterol efflux, and antiinflammatory and antioxidant properties. These appealing in-vitro findings still need to be validated in relevant human in vivo models.
Humoral autoimmune response to apoA-1/HDL In humans, low apoA-1 concentrations are associated not only with increased risk for cardiovascular disease, but also autoimmune diseases, such as rheumatoid arthritis and systemic lupus erythematosus (SLE) [29] . In accordance with these observations in humans, hypercholesterolaemic mice lacking plasma apoA-1 display an increased susceptibility to autoimmunity characterised by enlarged lymph nodes, cellular activation and proliferation, as well as lipid accumulation [62] . Autoantibodies to apoA-1 have been primarily shown to be increased in autoimmune conditions associated with increased cardiovascular risk, such as SLE [63, 64] , primary antiphospholipid syndrome [65] , and subsequently in patients with rheumatoid arthritis [66, 67] , as well as in patients suffering from acute coronary syndromes (ACS) [68] [69] [70] and severe carotid stenosis [71] . In ACS and rheumatoid arthritis patients, high levels of these autoantibodies were found to predict independently poor cardiovascular prognosis [67, 72] . From a pathophysiological point of view, these autoantibodies elicit a direct proinflammatory effect through TLR2/CD14 complex signalling [73] and neutrophil chemotaxis in vitro, as well as promoting atherogenesis and atherosclerotic plaque vulnerability in vivo [71] . Furthermore, these autoantibodies have also been shown in vitro to act as a positive chronotropic agent in the presence of aldosterone [72] , an effect recently attributed to a protein kinase A-dependent L-type calcium channel activation [74] . Furthermore, in some circumstances anti-apoA-1 autoantibodies have been associated with a decrease in the beneficial anti-inflammatory effects of apoA-1. Indeed, clinical and animal studies indicate that those autoantibodies impeded some of the HDL-related antiatherogenic properties, leading to dysfunctional HDLs. In SLE and primary antiphospholipid syndrome patients, as well as in lupus-prone mice, the presence of these autoantibodies was associated with a decrease in the antioxidant properties of HDL due to decreased PON-1 activity [64, 75, 76] , and increased proinflammatory ROS levels [65] .
Whether the existence of these apoA-1 antibodies is the cause or the consequence of the aforementioned apoA-1 modifications is still unclear. In favour of the former hypothesis would be that MPO or apoA-1 modifications mediated by reactive carbonyls give rise to neo-epitopes, followed by the appearance of autoantibodies. On the other hand, antibodies may act as oxidative proteins generating a pro-oxidant microenvironment through their ability to generate ROS via water oxidation [77] . If this effect optimises the affinity of antibodies for their target [78] , it is possible that such antibody-related oxidative properties could induce oxidative modifications in their target. In this scenario, autoantibodies to apoA-1/HDL may lead to the formation of proinflammatory apoA-1/HDLs. Further work is required to confirm or reject those hypotheses. Finally, as hormones markedly influence autoimmune diseases, and the oestrogen/androgen balance determines the synthesis of apoA-1 in the liver [79] , it is essential to find out whether the hormonal environment could modulate the occurrence of anti-apoA-1 antibodies. All these aspects are summarised in figure 2.
Conclusions and perspectives
ApoA-1 displays pleiotropic anti-inflammatory properties by modulating the innate inflammatory response at the [80, 81] casts doubt on the "HDL-raising hypothesis". The oneyear cardiovascular mortality increase observed with torcetrapib (prompting study interruption) has been attributed to aldosterone-related off-target effects of this molecule and to deleterious effects on endothelial function [82, 83] , but the reasons for the failure of dalcetrapib, devoid of such deleterious properties, to prevent cardiovascular disease despite raising HDL levels effectively are still unclear [81, 84] . The results of ongoing trials involving two other promising CETP inhibitors (anacetrapib and evacetrapib) are therefore eagerly awaited before any firm conclusion can be drawn about the efficacy of these therapeutic agents to prevent cardiovascular disease. In conclusion, the failures of CETP inhibitors to prevent cardiovascular disease despite inducing a sustained HDL increase stress the clinical importance of understanding the mechanisms and the circumstances driving apoA-1 and HDL towards pro-or anti-inflammatory molecules. These results also suggest that in parallel to in-vitro models of cholesterol efflux, models testing the proinflammatory response should be highly encouraged in order to determine the potential future therapeutic benefit of apoA-1 and apoA-1 mimetic peptides. Nevertheless, because these hypotheses are currently without any clinical evidence, and because no consensus exists on how HDL functionality should be determined, no rapid changes in the current management of dyslipidaemia and cardiovascular risk stratification [85] are expected to occur.
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